Molecularly targeted cancer therapies, such as small-molecule kinase inhibitors and
monoclonal antibodies, constitute a rapidly growing and an important part of the oncology …

Systemic administration of antiangiogenic drugs that target components of the vascular
endothelial growth factor A (VEGF-A; VEGF) signal transduction pathway has become a …

Systemic therapies established in the management of patients with neuroendocrine tumors
(NETs) include somatostatin analogs and interferon-α, also referred to as biotherapy. Recent …

Tyrosine kinase inhibitors (TKIs) have improved outcome for many tumors. Although better
tolerated than cytotoxic chemotherapy, they may cause several adverse events (AEs) and …

Recently, tyrosine kinase inhibitors (TKI) and immune checkpoint inhibitors (ICPIs) have
emerged as new classes of anticancer therapies. Although generally considered less toxic …

Cancer immunotherapy and targeted therapy, though less toxic than conventional
chemotherapy, can increase the risk of thyroid dysfunction. Immune checkpoint inhibitors …

Abstract In 2017, the Japan Society of Clinical Oncology (JSCO) published the JSCO
Clinical Practice Guidelines 2017 for Fertility Preservation in Childhood, Adolescent, and …

Tyrosine kinase inhibitors (TKI) belong to a new class of molecular multitargeted anticancer
therapy which targets different growth factor receptors and hence attenuates cancer cell …

Introduction: Recently, tyrosine kinase inhibitors (TKIs) have emerged as a new class of
anticancer therapy. Although generally considered less toxic than cytotoxic chemotherapy …

Background: Recent successes with immune checkpoint inhibitors (ICIs) and tyrosine kinase
inhibitors (TKIs) for the treatment of solid malignancies have paved the way for a new era of …